Defining the best available treatment for neurocytomas in children
- PMID: 15494975
- DOI: 10.1002/cncr.20695
Defining the best available treatment for neurocytomas in children
Abstract
Background: In children, neurocytomas are extremely rare tumors in the central nervous system. Since this entity was introduced in 1982, approximately 60 cases have been reported among patients age </= =18 years of age. The current analysis was performed to define the best available neurocytoma therapy in children.
Methods: All reported neurocytoma cases were reviewed for age, extent of resection, radiotherapy, radiotherapy dose, local control, and survival. Data were obtained from the literature and the authors. Statistical analysis was performed with the Kaplan-Meier method and log-rank test.
Results: Fifty-nine children were categorized by therapy: complete tumor resection (CTR; n = 20), complete tumor resection plus radiotherapy (CTR-RT; n = 11), incomplete tumor resection (ITR; n = 14), and incomplete tumor resection plus radiotherapy (ITR-RT; n = 14). Local control rates were better after CTR, CTR-RT, and ITR-RT than after ITR, at 5 years (86%, 100%, and 100% vs. 60%; P < 0.001) and at 10 years (86%, 100%, and 100% vs. 45%; P < 0.001). The 5-year and 10-year survival rates were 100% after CTR, 100% after CTR-RT, 100% after ITR-RT, and 93% after ITR (P = 0.4). In the ITR-RT group, no difference was observed between doses </= 50 gray (Gy) and >/= 54 Gy when compared for local control (P = 1.0) and survival rates (P = 1.0). Radiotherapy-related psychomotor retardation or secondary brain tumors were not reported.
Conclusions: The prognosis of children with neurocytomas is extremely good. CTR was associated with better local control and survival rates than ITR. After ITR, radiotherapy improves local control, but not survival. If postoperative radiotherapy is considered, a dose of 50 Gy was appropriate for long-term local control in children, whereas higher doses were required in adults.
(c) 2004 American Cancer Society
Similar articles
-
Therapy of meningeal melanocytomas.Cancer. 2004 Jun 1;100(11):2442-7. doi: 10.1002/cncr.20296. Cancer. 2004. PMID: 15160350
-
Well-differentiated neurocytoma: what is the best available treatment?Neuro Oncol. 2005 Jan;7(1):77-83. doi: 10.1215/S1152851704000584. Neuro Oncol. 2005. PMID: 15701284 Free PMC article.
-
[Treatment for central neurocytoma: a meta-analysis based on the data of 358 patients].Strahlenther Onkol. 2003 Apr;179(4):213-8. doi: 10.1007/s00066-003-1061-9. Strahlenther Onkol. 2003. PMID: 12707710 German.
-
Treatment of atypical neurocytomas.Cancer. 2004 Feb 15;100(4):814-7. doi: 10.1002/cncr.20032. Cancer. 2004. PMID: 14770439 Review.
-
Treatment recommendations for the various subgroups of neurocytomas.J Neurooncol. 2006 May;77(3):305-9. doi: 10.1007/s11060-005-9047-3. Epub 2006 Mar 31. J Neurooncol. 2006. PMID: 16575540 Review.
Cited by
-
Central neurocytomas in children: Clinicopathologic features and long-term surgical outcomes.Childs Nerv Syst. 2023 Jan;39(1):141-150. doi: 10.1007/s00381-022-05663-9. Epub 2022 Sep 12. Childs Nerv Syst. 2023. PMID: 36094604
-
Extraventricular neurocytoma in the left temporal lobe: A case report and review of the literature.Oncol Lett. 2016 Jun;11(6):3579-3582. doi: 10.3892/ol.2016.4487. Epub 2016 Apr 21. Oncol Lett. 2016. PMID: 27313678 Free PMC article.
-
Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis.Brain Tumor Res Treat. 2022 Jan;10(1):22-28. doi: 10.14791/btrt.2022.10.e30. Brain Tumor Res Treat. 2022. PMID: 35118844 Free PMC article.
-
Neurocytoma: a comprehensive review.Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285. doi: 10.1007/s10143-006-0030-z. Epub 2006 Aug 29. Neurosurg Rev. 2006. PMID: 16941163 Review.
-
Congenital extraventricular neurocytoma with atypical features in a 3-day-old neonate.Childs Nerv Syst. 2024 Dec 21;41(1):64. doi: 10.1007/s00381-024-06725-w. Childs Nerv Syst. 2024. PMID: 39708128
MeSH terms
LinkOut - more resources
Full Text Sources
Medical